Candriam S.C.A. Purchases 5,610 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Candriam S.C.A. grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 24.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 28,544 shares of the company’s stock after buying an additional 5,610 shares during the period. Candriam S.C.A.’s holdings in IDEXX Laboratories were worth $11,801,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Retirement Wealth Solutions LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $31,000. Ashton Thomas Securities LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $37,000. Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $38,000. Finally, Crews Bank & Trust bought a new stake in shares of IDEXX Laboratories in the 4th quarter worth approximately $41,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of recent research reports. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Finally, Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Trading Up 0.3 %

IDXX stock opened at $430.12 on Friday. The business has a fifty day moving average price of $437.37 and a 200 day moving average price of $449.72. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $574.94. The stock has a market capitalization of $34.98 billion, a price-to-earnings ratio of 40.31, a P/E/G ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.